The Hon. (Dr.) Nalinda Jayatissa

¶ 01 Mr. Speaker, in reply to the question raised by Hon. Marikkar:

¶ 02 (a) (i) There are 41 clinics across the country for testing and treatment of sexually transmitted diseases and AIDS.

¶ 03 (ii) Patient numbers: - 4,771 - 1,409 - 1,035 - 2,891

¶ 04 (iii) Yes. Since 2025.11.06 a permanent Director has been appointed.

¶ 05 (iv) Does not arise.

¶ 06 (b) (i) As at 2025.12.31, there is a stock of 36,420 tablets of pre-exposure prophylaxis, sufficient for four months.

¶ 07 (ii) Yes.

¶ 08 (iii) 1. The Global Fund 2. Family Planning Association of Sri Lanka

¶ 09 (iv) Currently funded by the Global Fund; in future, Government funds (budgetary) will be used. As an urgent need, supplies were recently provided by the Sri Lanka Family Planning Association.

¶ 10 (c) (i) The three ARVs referred to—Tenofovir, Lamivudine, Dolutegravir—are administered as a combined formulation known as TLD. As at 31 December 2025, the TLD stock was 101,280.

¶ 11 (ii) There is currently no shortage of essential ARVs for AIDS patients. Due to a delay in expected Global Fund deliveries, the dispensing period was temporarily reduced from three months to one month, but supplies are now due, and the period will be extended back to three months immediately upon receipt. Dispensing never stopped.

¶ 12 (iii) Responsibility for uninterrupted supply rests with the National STD/AIDS Control Programme and the Medical Supplies Division.

¶ 13 (iv) At present, there is no shortage of essential medicines for AIDS patients.

¶ 14 (d) Does not arise.